AngioDynamics (ANGO) awards director Michael Tarnoff 11,887 shares

Rhea-AI Filing Summary

Tarnoff Michael E reported acquisition or exercise transactions in this Form 4 filing.

AngioDynamics director Michael E. Tarnoff received a grant of 11,887 shares of common stock on July 15, 2026, representing restricted stock units granted as regular annual director compensation that immediately vested at grant. After this award, he directly holds 95,265 common shares, and the transaction was not made under a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Buyer: 11,887 shares

Net Buy 1 txn

Insider Tarnoff Michael E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	11,887	$0.00	$0.00

Holdings After Transaction: Common Stock — 95,265 shares (Direct)

Footnotes (1)

1. F1. The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant.

Key Figures

Shares granted: 11,887 shares Shares owned after grant: 95,265 shares Reported grant price per share: $0.0000

3 metrics

Shares granted 11,887 shares Restricted stock units granted as regular annual compensation for director service

Shares owned after grant 95,265 shares Direct common stock holdings following the July 15, 2026 award

Reported grant price per share $0.0000 Transaction price per share shown for the stock award

Key Terms

restricted stock units, annual compensation, immediately vested

3 terms

restricted stock units financial

"represents 11,887 restricted stock units granted as regular annual compensation"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

annual compensation financial

"restricted stock units granted as regular annual compensation for service as a director"

immediately vested financial

"The restricted stock units immediately vested at the time of grant."

FAQ

What insider transaction did AngioDynamics (ANGO) disclose for Michael E. Tarnoff?

AngioDynamics disclosed that director Michael E. Tarnoff received 11,887 shares of common stock as a stock award. These shares represent restricted stock units granted as regular annual compensation for his board service and immediately vested at the time of grant on July 15, 2026.

How many AngioDynamics (ANGO) shares does Michael E. Tarnoff own after this Form 4 event?

Following the grant, Michael E. Tarnoff directly owns 95,265 AngioDynamics common shares. This total reflects the addition of 11,887 shares received through immediately vested restricted stock units granted as part of his regular annual compensation for serving as a director.

Was the AngioDynamics (ANGO) Form 4 transaction under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not marked, indicating the reported transaction was not executed under a Rule 10b5-1 trading plan. Instead, it reflects a compensation-related grant of immediately vested restricted stock units for board service.

Did Michael E. Tarnoff buy AngioDynamics (ANGO) shares on the open market in this filing?

No. The Form 4 shows an “A” code grant of 11,887 shares at a reported price of $0.0000 per share. Footnotes clarify this was a stock award via restricted stock units for annual director compensation, not an open-market purchase or sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/22/2026 - 08:06 PM Accepted by SEC EDGAR 07/22/2026 - 08:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tarnoff Michael E

(Last) (First) (Middle)

14 PLAZA DRIVE

(Street)

LATHAM NEW YORK 12110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANGIODYNAMICS INC [ ANGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		A		11,887(1)	A	$0	95,265	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant.

	/s/ Lawrence T. Weiss, Attorney in Fact	07/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)